Investor Overview - OBI Pharma

2026.Mar.03

News

OBI Receives Acceptance of Ten Abstracts at 2026 AACR
Advances Next-Generation ADC Development and Global Partnerships

2026.Feb.24

News

OBI Presents Next-Generation Bispecific Dual-Payload ADC Development at World ADC London 2026

2025.Dec.19

News

OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC

2026.Mar.10

Announcement

Change the Agent for stock affairs

2026.Mar.09

Announcement

The Company's Board of Directors resolved to convene the 2026 Annual General Shareholders' Meeting

2026.Mar.09

Announcement

Announcement of the Company’s accumulated losses have reached one-half of paid-in capital

2024 Annual Report

Learn how we created value in 2024 and worked to pursue our purpose of enabling a healthier world.

Featured
Presentation

2025 Investors' Meeting - Driving Value Transformation Through ADC Innovation

2025 First Extraordinary General Shareholders’ Meeting

2025.Oct.20 at 09:00 AM
Taipei Bioinnovation Park 1F Conference Room

Shareholder Meeting Notice

Shareholder Meeting Handbook

Shareholder Meeting Minutes

Governance

Corporate
Overview

Board of
Directors

Special
Committee

Integrity

Internal
Audit

Governance
Document

Investor Relations

IR Office

Phone: 02-2655-8799 #312

Email: InvestorRelations@obipharma.com

01

Corporate Overview

02

Annual Report

03

Financial Report